RJA
RARE icon

Raymond James & Associates’s Ultragenyx Pharmaceutical RARE Stock Holding History

Raymond James & Associates’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$1.13M Sell
20,266
-399
-2% -$20.3K ﹤0.01% 2618
2024
Q2 		$849K Buy
20,665
+144
+0.7% +$6.15K ﹤0.01% 2739
2024
Q1 		$958K Buy
20,521
+5,766
+39% +$272K ﹤0.01% 2621
2023
Q4 		$706K Sell
14,755
-2,991
-17% -$116K ﹤0.01% 2732
2023
Q3 		$633K Sell
17,746
-9,055
-34% -$359K ﹤0.01% 2740
2023
Q2 		$1.24M Buy
26,801
+2,733
+11% +$127K ﹤0.01% 2352
2023
Q1 		$965K Buy
24,068
+4,234
+21% +$182K ﹤0.01% 2467
2022
Q4 		$919K Buy
19,834
+8,990
+83% +$354K ﹤0.01% 2480
2022
Q3 		$449K Sell
10,844
-2,662
-20% -$137K ﹤0.01% 2938
2022
Q2 		$806K Sell
13,506
-376
-3% -$23.1K ﹤0.01% 2592
2022
Q1 		$1.01M Buy
13,882
+4,373
+46% +$304K ﹤0.01% 2592
2021
Q4 		$800K Sell
9,509
-329
-3% -$26.8K ﹤0.01% 2775
2021
Q3 		$887K Buy
9,838
+397
+4% +$35.9K ﹤0.01% 2662
2021
Q2 		$900K Sell
9,441
-6,277
-40% -$654K ﹤0.01% 2659
2021
Q1 		$1.79M Buy
15,718
+5,990
+62% +$815K ﹤0.01% 2093
2020
Q4 		$1.35M Buy
9,728
+3,612
+59% +$428K ﹤0.01% 2139
2020
Q3 		$503K Buy
6,116
+278
+5% +$23K ﹤0.01% 2618
2020
Q2 		$457K Buy
+5,838
New +$386K ﹤0.01% 2646
2018
Q2 		– Sell
-5,231
Closed -$267K – 3657
2018
Q1 		$267K Sell
5,231
-1,140
-18% -$57.4K ﹤0.01% 2960
2017
Q4 		$295K Sell
6,371
-877
-12% -$43K ﹤0.01% 2841
2017
Q3 		$386K Buy
7,248
+138
+2% +$8.18K ﹤0.01% 2633
2017
Q2 		$442K Buy
7,110
+1,812
+34% +$109K ﹤0.01% 2497
2017
Q1 		$359K Sell
5,298
-177
-3% -$13.5K ﹤0.01% 2586
2016
Q4 		$385K Sell
5,475
-6,403
-54% -$454K ﹤0.01% 2492
2016
Q3 		$843K Buy
11,878
+7,129
+150% +$455K ﹤0.01% 1982
2016
Q2 		$232K Sell
4,749
-6,242
-57% -$404K ﹤0.01% 2566
2016
Q1 		$696K Buy
+10,991
New +$719K ﹤0.01% 1863

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Raymond James & Associates's RARE Position: Q3 2024 in Review

Raymond James & Associates reduced its Ultragenyx Pharmaceutical (RARE) stake by 1.9% in Q3 2024, selling an estimated $20.3K and leaving 20,266 shares worth $1.13M. The position accounts for ﹤0.01% of the portfolio, ranked #2618.

Raymond James & Associates first reported a position in RARE in Q1 2016 and has held it in 27 quarters since. The position peaked at $1.79M in Q1 2021. 300 funds tracked by Wall St. Rank hold RARE as of Q3 2024.

  • Raymond James & Associates held 20,266 shares of Ultragenyx Pharmaceutical worth $1.13M as of Q3 2024.
  • Raymond James & Associates sold 399 Ultragenyx Pharmaceutical shares in Q3 2024, an estimated $20.3K.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Raymond James & Associates's portfolio in Q3 2024, its #2618 holding.
  • Raymond James & Associates first reported a position in Ultragenyx Pharmaceutical in Q1 2016 and has held it in 27 quarters since.
  • Raymond James & Associates's Ultragenyx Pharmaceutical position peaked at $1.79M in Q1 2021.
  • 300 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q3 2024.

Based on Raymond James & Associates's 13F filing for Q3 2024, filed 18 Oct 2024.